Advertisement

Topics

Bluebird Bio's gene therapy for beta thalassemia gains EMA PRIME status

05:15 EDT 22 Sep 2016 | SmartBrief

Bluebird Bio's LentiGlobin BB305 gene therapy has been granted access to the European Medicines Agency's Priority Medicines,  -More

Original Article: Bluebird Bio's gene therapy for beta thalassemia gains EMA PRIME status

NEXT ARTICLE

More From BioPortfolio on "Bluebird Bio's gene therapy for beta thalassemia gains EMA PRIME status"

Quick Search
Advertisement
 

Relevant Topic

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...